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Indicators for early assessment of palliative
care in lung cancer patients: a population
study using linked health data
Maria Kelly1* , Katie M. O’Brien2, Michael Lucey3, Kerri Clough-Gorr2 and Ailish Hannigan4

Abstract
Background: Analysing linked, routinely collected data may be useful to identify characteristics of patients with
suspected lung cancer who could benefit from early assessment for palliative care. The aim of this study was to
compare characteristics of newly diagnosed lung cancer patients dying within 30 days of diagnosis (short term
survivors) with those surviving more than 30 days. To identify indicators for early palliative care assessment we
distinguished between characteristics available at diagnosis (age, gender, smoking status, marital status, comorbid
disease, admission type, tumour stage and histology) from those available post diagnosis. A second aim was to
examine the association between receiving any tumour-directed treatment, place of death and survival time.
Methods: A retrospective observational population based study comparing lung cancer patients who died within
30 days of diagnosis (short term survivors) with those who survived longer using Chi-squared tests and logistic
regression. Incident lung cancer (ICD-03:C34) patients diagnosed 2005–2012 inclusive who died before 01–01-2014
(n = 14,228) were identified from the National Cancer Registry of Ireland linked to death certificate data and acute
hospital episode data.
Results: One in five newly diagnosed lung cancer patients died within 30 days of diagnosis. After adjusting for stage
and histology, death within 30 days was higher in patients who were aged 80 years or older (adjusted OR 2.46; 95%CI
2.05–3.96; p < 0.001), patients with emergency admissions at diagnosis (adjusted OR 2.96; 95%CI 2.61–3.37; p < 0.001)
and patients with any comorbidities at diagnosis (adjusted OR 1.32 95%CI 1.15–1.52; p < 0.001). Overall, 75% of those
who died within 30 days died in hospital compared to 43% of longer term survivors.
Conclusions: We have shown a high proportion of lung cancer patients who die within 30 days of diagnosis are older,
have comorbidities and are admitted through the emergency department. These characteristics, available at diagnosis,
may be useful prognostic factors to guide decisions on early assessment for palliative care for lung cancer patients.
Patients who die shortly after diagnosis are more likely to die in hospital so reporting place of death by survival time
may be useful to evaluate interventions to reduce deaths in acute hospitals.
Keywords: Lung cancer, Palliative care, Survival time, Administrative health data

* Correspondence: m.kelly@ncri.ie
1
National Cancer Registry Ireland and Graduate Entry Medical School,
University of Limerick, Limerick, Ireland
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Kelly et al. BMC Palliative Care (2018) 17:37

Background
Worldwide, lung cancer remains the most common cancer
and was the cause of over 1.6 million deaths in 2012. In
Europe 12.1% of all incident cancers in 2012 were lung
cancer and it accounted for 20.1% of all cancer deaths [1].
Typically lung cancer is characterised by short survival
times, often attributed to late diagnosis [2, 3]. The UK and
Ireland have the poorest one- and five- year relative
survival rates for lung cancer in Northern Europe [4].
In the UK just over one third of patients survive more than
1 year following a lung cancer diagnosis (2010–2011) [5].
Most patients with advanced cancer die in hospital [6]
although a review of 210 studies from 33 countries
found most people would prefer to die at home [7].
Bekelman et al. reported death rates in acute hospitals
ranging from 54% in Canada to just over 20% in the
United Sates for lung cancer decedents over 65 years of
age in 2010 across 6 developed countries [8]. Early
palliative care in patients with metastatic non-small-cell
lung cancer has been found to improve survival times
and lead to less aggressive care at end of life compared
to patients receiving standard care [9]. It also improves
patients understanding of their prognosis which may
lead to more informed choices near end of life [10].
Identifying those in need of early assessment for palliative
care involves understanding prognostic factors of survival
i.e. factors measured before treatment that have an impact
on a patient’s outcome “independently” of received or
general class of treatment (Paesmans, 2012). In the case
of lung cancer clinical stage and functional status are
two important prognostic factors for survival while age
and gender are, to a lesser extent, also important [11].
The potential of using linked routine health data for
prognostication has increasingly been recognised [12].
Data from multiple sources (registries, death certificates,
hospital and community-based healthcare records) can be
used retrospectively to identify those with unique needs or
at risk of poorer outcomes [13–16].
The aim of this study was to use linked routine data to
compare characteristics of newly diagnosed lung cancer
patients dying within 30 days of diagnosis (short term
survivors] with those surviving more than 30 days. To
identify indicators for early palliative care assessment we
distinguished between characteristics available at diagnosis
(age, gender, smoking status, marital status, comorbid
disease, admission type, tumour stage and histology) from
those available post diagnosis. A second aim was to examine
the association between receiving any tumour-directed
treatment, place of death and survival time.
Methods
Data sources

The data sources for this study were the National Cancer
Registry Ireland (NCRI), the hospital inpatient enquiry
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(HIPE) database from the Economic and Social Research
Institute (ESRI) and death certificate (DC) data from the
Central Statistics Office (CSO).
The NCRI records demographic, clinical and treatment
information for all cancers diagnosed in the Irish population, according to internationally accepted conventions.
The registry obtains data on patients with cancer from a
variety of sources but primarily via qualified cancer data
registrars who are employed by the registry and based in
the major acute hospitals around the country. The main
source of notification of each new case is a pathology
report. The second main source of notification is HIPE.
HIPE is an electronic based information system that
records demographic, clinical and administrative data
on discharges from all acute public hospitals in Ireland.
Each public hospital produces an annual HIPE list
which identifies all cases of cancer discharged from the
hospital during that year; HIPE allows the registry to
identify cases that have not had a histological verification of
the diagnosis, or for which the registry failed to identify a
pathology report. For data confidentiality reasons, only
HIPE inpatient episodes that mention a cancer diagnosis are
made available to the registry so episodes prior to a cancer
diagnosis are not provided. It is a legal requirement in
Ireland that every death that takes place in the State must
be recorded and registered within 3 months. Population
based death certificate data on date, cause and place of
death of all decedents is provided by the CSO.
The cancer registry routinely links HIPE data and death
certificate data to cancer registry data using probabilistic
matching techniques, for case ascertainment and verification purposes. Completeness of case ascertainment for
lung cancer is estimated to be 98.7% [17].
Data definitions

Information collected by the registry is coded and classified
according to international guidelines including international
classification of diseases (ICD) codes, definitions of incidence and how multiple tumours are handled [18]. The
date of diagnosis is taken as the date of incidence which is
selected from a hierarchy of dates in the following order,
the date of first histological confirmation of malignancy or
in the absence of histological confirmation, the date of first
treatment (excluding “seen but not treated”), followed by
the date of admission to hospital because of the malignancy
[18, 19]. Stage at diagnosis was defined according to
American Joint Committee on Cancer (AJCC) summary
staging [20]. Histological groupings were based on the
International Agency for Research on Cancer classification
[21]. Treatment data were classified to a yes/no category
for any tumour-directed surgery, chemotherapy or radiotherapy received within 1 year of diagnosis.
The diagnosis episode was the inpatient episode during
which the lung cancer diagnosis was made. For a small
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proportion of patients (10%) the diagnosis date didn’t
occur during an inpatient episode so the episode occurring
in the interval from 7 days before to 14 days after the lung
cancer diagnosis date was used. HIPE records episode
admissions as either emergency or elective. Emergency
admissions occur when a patient requires immediate care
and treatment as a result of a severe, life threatening or
potentially disabling condition with the patient generally
admitted through the Emergency Department. Elective
admissions occur when the patient’s condition permits
adequate time to schedule the availability of suitable
services to the patient [22]. A co-morbidity score for
each patient, based on the updated Charlson index [23]
was derived from all diagnoses recorded in HIPE for
the diagnosis episode. The Charlson comorbidity index
(CCI) predicts the one-year mortality for a patient who
may have a range of 17 comorbid conditions. Each condition is assigned a score of 1, 2, 3, or 6, depending on the
risk of dying associated with each one. Scores are summed
to provide a total score to predict mortality. Patients were
classified to three comorbidity categories ‘None’, ‘1’ and ‘> 1’
based on their Charlson score. The lung cancer diagnosis
was disregarded when calculating the co-morbidity score.
For every episode, HIPE records a discharge code
describing where the patient was discharged to, including
categories for home, nursing home, died with and without
post mortem and transfer to another hospital. For this
analysis we classified discharge code to ‘Death’ and
‘Other’.
Setting/participants

All incident lung cancer patients (ICD-O3:C34) [24],
who were diagnosed in Ireland between 2005 and 2012
and who died before 01–01-2014 were identified from
the NCRI. These records were linked to HIPE and death
certificate data.
Outcome variable

To identify early indicators for palliative care assessment,
patients were classified to those who died within 30 days
of diagnosis (short term survivors) and those who survived
more than 30 days. We chose the 30 day cut-off for a
number of reasons i.) 30 day mortality has been used
previously as an indicator of early mortality for newly
diagnosed breast or colorectal cancer patients in
Scotland [25] and to assess factors affecting 30-day
mortality in a national patient population of lung and
breast cancer patients receiving systemic anti-cancer
therapy [26], ii.) it aligns with our study objective of
identifying patient cohorts who might benefit from
early assessment for palliative care as these patients are
unlikely to have gained survival benefits of treatment, iii.)
lung cancer is characterised by short survival times and in
our study just over 20% of patients died within 30 days of
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diagnosis providing a natural cut point for this analysis
and iv.) it is easily derived from routine data and can
facilitate comparisons across health systems.
The association between receiving any tumour-directed
treatment, place of death and survival time as a continuous
variable was explored graphically.
Statistical analysis

Chi-squared tests for independence were used to test for
significant associations between categorical variables i.e.
patient demographic variables present at diagnosis (age,
gender, smoking status and marital status); clinical variables at diagnosis (stage, histology and any comorbidities);
characteristics of the diagnosis episode (admission type i.e.
elective or emergency and whether death occurred in
hospital during the diagnosis episode); post diagnostic
characteristics including receipt of any tumour-directed
treatment, cause of death and place of death; and survival
time (≤ 30 days, > 30 days) using a 5% level of significance.
Cramer’s V was used as a measure of the strength of the
association with nominal variables. Somers’ D was used
as a measure of the strength of the association between
ordinal independent variables and stratified survival time.
Multivariable logistic regression analysis was used to
predict death within 30 days of diagnosis (yes, no). The
model was fitted in a two stage process; the first stage
examined the impact of patient characteristics immediately
available at presentation. Next, the impact of clinical variables (e.g. histology and staging of tumour) were assessed
by adding these to the model. Model goodness-of-fit was
checked using the Hosmer and Lemeshow test [27]. The R
statistical package was used for data analyses [28].

Results
Of the 16,638 incident lung cancer patients diagnosed
between 2005 and 2012 inclusive, 14,228 (85.5%) died
before 01–01-2014. Of these, 383 cases were notified
from death certificate data only and due to insufficient
data are excluded from the analysis, leaving 13,845 cases
in the final dataset. Median survival time was 137 days
with an interquartile range (IQR) of 44–339 days.
Almost one in five (n = 2595, 18.7%) newly diagnosed
lung cancer patients died within 30 days of diagnosis.
Table 1 shows the characteristics of the short term
survivors compared to those who lived more than 30
days. The strongest association with short term survival
were emergency admission at diagnosis, comorbidities at
diagnosis, tumour histology and tumour stage. Compared
with longer-term survivors, short term survivors were
more likely to be admitted as emergencies at diagnosis
(84% versus 52%), they were more likely to have comorbidities at diagnosis (18% versus 13% had a Charlson score
of 1 and 19% versus 12% scored > 1), and were less likely
to have their tumour characterised (37% versus 15% were
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Table 1 Patient, tumour and admission characteristics at diagnosis, by survival category
Survival category
0–30 days
n = 2595

> 30 days
n = 11,250

All
n = 13,845

Tests of association

< 60

253 (10)

1990 (18)

2243 (16)

60–69

569 (22)

3240 (29)

3809 (28)

χ2 = 268.78, df(3), p < 0.001
Somers’ d = 0.082

70–79

950 (37)

3835 (34)

4785 (35)

80+

823 (32)

2185 (19)

3008 (22)

Male

1606 (62)

6671 (59)

8277 (60)

Female

989 (38)

4579 (41)

5568 (40)

Partner

1224 (47)

6193 (55)

7417 (54)

Other

1371 (53)

5057 (45)

6428 (46)

Ever

1803 (69)

8641 (77)

10,444 (75)

Never

219 (8)

915 (8)

1134 (8)

Unknown

573 (22)

1694 (15)

2267 (16)

Elective

360 (16)

3990 (46)

4350 (40)

Emergency

1823 (84)

4669 (54)

6492 (60)

0

1362 (62)

6481 (75)

7843 (72)

1

403 (18)

1166 (13)

1569 (15)

>1

418 (19)

1012 (12)

1430 (13)

Stage 0/I/II

183 (7)

2148 (19)

2331 (17)

Stage III

573 (22)

3246 (29)

3819 (28)

Stage IV

1376 (53)

4606 (41)

5982 (43)

Un-staged

463 (18)

1250 (11)

1713 (12)

447 (17)

3027 (27)

3474 (25)

Age group

Gender
χ2 = 5.88, df(1), p = 0.015
Cramer’s V = 0.021

Marital status
χ2 = 52.66, df(1), p < 0.001
Cramer’s V = 0.062

Smoker
χ2 = 78.77, df(3), p < 0.001
Cramer’s V = 0.075

a

Diagnosis episode admission

χ2 = 635.33, df(1), p < 0.001
Cramer’s V = 0.242

Diagnosis episode Charlson scorea
χ2 = 134.08, df(2), p < 0.001
Cramer’s V = 0.114

Stageb
χ2 = 365.11, df(3), p < 0.001
Somers’ d = 0.098

c

Histology

Adenocarcinoma
Carcinoma

254 (10)

1346 (12)

1600 (12)

Large cell carcinoma

121 (5)

421 (4)

542 (4)

Unspecified malignant

951 (37)

1715 (15)

2666 (19)

Small cell carcinoma

449 (17)

1708 (15)

2157 (16)

Squamous cell carcinoma

373 (14)

3033 (27)

3406 (25)

χ2 = 735.46, df(5), p < 0.001
Cramer’s V = 0.23

a

The diagnosis episode was the episode where the lung cancer diagnosis was made or the first episode occurring in the interval from 7 days before to 14 days
after the lung cancer diagnosis. Episodes outside this interval were excluded from the analysis, n = 1591. There was no matching HIPE data for n = 1412
decedents. The denominator data is n = 2183 for short term survivors and n = 8659 for longer term survivors
b
Due to small cell numbers (n = 11), ‘Stage 0’ classification was merged with ‘Stage I/II’ classification
c
Due to small cell numbers (n = 21), ‘Sarcoma’ classification was merged with ‘unspecified malignant’ classification. Morphologies based on International Agency
for Research on Cancer classification [21]

histologically unspecified and 18% versus 11% were
unstaged). Table 2 shows the results of the multivariable
logistic regression analysis adjusted for characteristics
available at the diagnosis episode. These include gender,
marital status and comorbidities present at diagnosis.

Older patients (OR 2.72; 95%CI 2.29–3.24; p < 0.001),
those with emergency admissions at diagnosis (OR 3.92;
95%CI 3.47–4.44; p < 0.001) and those with comorbid
disease at diagnosis were significantly more likely to die
within 30 days of diagnosis; the odds increased from 1.23
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Table 2 Characteristics available at diagnosis associated with
death within 30 days of diagnosis
Characteristic

Adjusted odds ratio

95%
confidence interval

p-value for
Wald test

Age group

Characteristic

Adjusted odds 95%
p-value for
ratio
confidence interval Wald test

Age group

< 60 years

1.00

60–69 years

1.44

1.21

1.72

70–79 years

1.91

1.62

2.25

< 60 years

1.00

< 0.001

60–69 years

1.45

1.22

1.74

< 0.001

< 0.001

70–79 years

1.99

1.68

2.36

< 0.001

80+ years

2.70

2.27

3.22

< 0.001

80+ years

2.44

2.03

2.94

< 0.001

1.04

1.28

0.007

0.69

0.86

< 0.001

Marital status

Marital status

Partnered

1.00

Other

1.19

1.07

1.31

0.001

Gender

Partnered

1.00

Other

1.15

Gender

Male

1.00

Female

0.81

0.73

0.90

< 0.001

Smoker

Male

1.00

Female

0.77

Smoker

Ever

1.00

Never

0.98

0.82

1.17

0.906

Unknown

1.48

1.29

1.68

< 0.001

Diagnosis episode admissiona
Elective

1.00

Emergency

3.92

Ever

1.00

Never

0.91

0.75

1.09

0.313

Unknown

1.27

1.10

1.46

< 0.001

2.61

3.37

< 0.001

Diagnosis episode admissiona

3.47

4.44

< 0.001

a

Diagnosis episode Charlson score
0

Table 3 Characteristics and clinical data available at diagnosis
associated with death within 30 days of diagnosis

Elective

1.00

Emergency

2.96

Diagnosis episode Charlson score
0

1.00

1.00

1

1.23

1.08

1.41

0.002

1

1.32

1.15

1.52

< 0.001

>1

1.41

1.23

1.62

< 0.001

>1

1.44

1.25

1.65

< 0.001

a

The diagnosis episode was the episode where the lung cancer diagnosis was
made or first episode occurring in the interval of 7 days before to 14 days after the
lung cancer diagnosis

(95%CI 1.08–1.41; p = 0.002) among patients with a CCI
score of 1 to 1.41 (95%CI 1.23–1.62; p < 0.001) among
patients with a CCI > 1. Table 3 shows the results of the
regression analysis adjusted for the clinical variables stage
and histology. After adjusting for stage and histological type,
older age (adjusted OR 2.46; 95%CI 2.05–2.96; p < 0.001)
emergency admission at diagnosis (adjusted OR 2.96; 95%CI
2.61–3.37; p < 0.001) and comorbid disease were still
strongly associated with death within 30 days of diagnosis;
the adjusted odds increased from 1.32 (95%CI 1.15–1.52;
p < 0.001) among patients with a CCI score of 1 to 1.44
(95%CI 1.25–1.65; p < 0.001) among patients with a CCI > 1.
Table 4 describes treatment received post diagnosis, the
discharge code for the diagnosis episode, the place of death
and the cause of death by survival category. Only 16% of the
short term survivors received tumour directed treatment
post diagnosis compared to 72% of the longer term survivors. Increasing survival time was associated with a steady
increase in the percentage receiving treatment (Fig. 1a).
The proportion dying in hospital decreased as survival
time increased to 90 days but tended to remain stable

Stage
Stage 0/I/II

1.00

Stage III

2.12

1.73

2.62

< 0.001

Stage IV

3.37

2.77

4.11

< 0.001

Un-staged

3.47

2.76

4.37

< 0.001

Histology
Adenocarcinoma

1.00

Carcinoma

1.17

0.97

1.41

0.095

Large cell

1.71

1.32

2.20

< 0.001

Unspecified
malignant

2.91

2.49

3.41

< 0.001

Small cell

1.50

1.28

1.76

< 0.001

Squamous cell

0.84

0.71

0.98

0.034

a

The diagnosis episode was the episode where the lung cancer diagnosis was
made or first episode occurring in the interval of 7 days before to 14 days after the
lung cancer diagnosis

after 90 days survival (Fig. 1b). Overall 75% of the short
term survivors died in hospital compared to 43% of longer
term survivors. The proportion recorded as dying from
lung cancer was similar in both groups - 89% short term
survivors and 90% longer term survivors had lung cancer
recorded as main cause of death.
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Table 4 Post diagnosis characteristics; treatment, place of death and cause of death
Survival category
0–30 days
n = 2595

> 30 days
n = 11,250

All
n = 13,845

Tests of association

2169 (84)

3183 (28)

5352 (39)

426 (16)

8067 (72)

8493 (61)

χ2 = 2718.36, df(1), p < 0.001,
Cramer’s V = 0.443

Death

1243 (57)

237 (3)

1480 (14)

Other

940 (43)

8422 (97)

9362 (86)

Hospital

1949 (75)

4850 (43)

6799 (49)

Home

338 (13)

3200 (28)

3538 (26)

Tumour directed treatmenta
None
Any
b

Diagnosis episode discharge code

χ2 = 4345.6 df(1), p < 0.001,
Cramer’s V = 0.633

Place of death

Hospice

185 (7)

2084 (19)

2269 (16)

Nursing Home

65 (3)

688 (6)

753 (5)

Unknown

34 (1)

339 (3)

373 (3)

No death certificate

24 (1)

89 (1)

113 (1)

Lung cancer

2320 (89)

10,081 (90)

12,401 (90)

Other

275 (11)

1169 (10)

1444 (10)

χ2 = 876.52, df(5), p < 0.001,
Cramer’s V = 0.252

Cause of death
χ2 = 0.096, df(1), p = 0.757,
Cramer’s V = 0.003

a

Refers to tumour directed treatment received within 1 year of diagnosis
b
The diagnosis episode was the episode where the lung cancer diagnosis was made or the first episode occurring in the interval from 7 days before to 14 days
after the lung cancer diagnosis. Episodes outside this interval were excluded from the analysis, n = 1591. There was no matching HIPE data for n = 1412
decedents. The denominator data is n = 2183 for short term survivors and n = 8659 for longer term survivors

Discussion
One in five newly diagnosed lung cancer patients in our
study died within 30 days of diagnosis and one quarter
died within 44 days. Given the very short survival times,
indicators for early assessment for palliative care are
important to facilitate ongoing management and end of
life care. We identified that older patients (aged 80 years
and over), with any comorbid disease, who have emergency
admissions at diagnosis are more likely to die within
30 days following diagnosis than younger patients, without
comorbidities and admitted electively.

Survival time

Our study aimed to identify indicators for early assessment
for palliative care using routine linked data to compare
characteristics of short- and longer term survivors. Survival
time is affected by many factors including patient age,
functional status, tumour stage at diagnosis and the treatment modalities available to treat disease. The relationships between these factors are complex; treatment plans
are optimised to the individual and patients well enough to
receive curative treatment will derive a survival benefit
from that treatment. Patient who die shortly after diagnosis
may have had too little time for adequate assessment and
appropriate care plans (curative or palliative) to be put in
place however, this group has not been well characterised

at the population level. We are aware of only one population based study characterising short term survivors
[25]. We have shown patients surviving longer are more
likely to receive tumour-directed treatment which is
associated with survival benefit, the proportion of
patients receiving treatment increased steadily with
increasing survival time.
Retrospective studies of cancer care often use look-back
periods from death of 6 or 12 months [29]. Survival times
vary considerably by cancer type and stratification by
survival time from diagnosis could be more informative
than look-back studies (using defined periods of time
before death). For example when examining the care
received at end of life, aggressive care may be completely
appropriate in the early stages of treatment shortly after a
cancer diagnosis however this information can be lost in
look-back studies if survival time is not reported. Reporting
survival time provides an added context to evaluate the
care patients receive at end of life. As we have shown it
can highlight opportunities to improve that care for patient
subgroups, for example patients who die very soon after
diagnosis.
Indicators for palliative care
Age and emergency admission

In a critical review of 10 studies from the USA, Canada,
France, Australia and New Zealand, Wong et al.
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Fig. 1 Percentage (a) receiving tumour–directed treatment and (b) place of death by survival time

highlighted the absence of evidence regarding the
palliative care requirements of older patients particularly those presenting to emergency departments, with a
call for more research to help improve service provision

[30]. Similarly Brewster et al. [25] found patients dying
within 30 days of diagnosis were more likely to be elderly
and have one or more emergency admission in the 30 days
either before or after diagnosis. Our population based

Kelly et al. BMC Palliative Care (2018) 17:37

study supports the international evidence for high levels
of emergency admissions and poorer survival in older
cancer patients.
Sixty percent of patients diagnosed with lung cancer in
our study presented as an emergency admission. McPhail
et al. also found emergency presentation remains predictive
of short-term mortality in cancer patients even when
age, stage, and co-morbidity are accounted for [31]. A
prospective mixed methods single centre study of lung
cancer patients presenting as emergencies reported palliative
care needs were high and various information and support
needs unmet [32]; the authors recommended a specialist
palliative care assessment be routinely offered.
A lack of access to cancer diagnostics is a recognised
short-coming in the Irish health system which has led to
increased referrals of patients to emergency departments
by general practitioners [33] and to initiatives to improve
access to care. In 2012, the National Cancer Control
Programme in Ireland initiated rapid access clinics
providing direct access to consultant led assessment
and diagnostic services for patients with suspected lung
disease or cancer [34]. The clinics allow for suspect
cases to be fast tracked and diagnosed on an urgent
basis thereby facilitating earlier diagnosis and increased
survival. Our study results (on patients diagnosed from
2005 to 2012) provides baseline data on stage at diagnosis
and survival for patients diagnosed before the introduction
of these rapid access clinics.
Comorbidity

Comorbid disease has been shown to delay diagnosis
in colorectal cancer patients and particularly in older
patients [35]; comorbid conditions were classified as
‘competing demands’ (unrelated to colorectal cancer)
or ‘alternative explanations’ (sharing symptoms with
colorectal cancer). In a prospective study across five
US hospitals, earlier consultation with specialist palliative
care teams was associated with lower cost of hospital stay
for patients admitted with an advanced cancer diagnosis
[36]. A second related study showed the effect was
larger for patients with higher number of comorbidities
[37]. Comorbidity was measured using the Elixhauser
comorbidity index [38] which counts the presence of
thirty one serious conditions. We used the Charlson
index [23] to derive a comorbidity score from the diagnosis
episode as we did not have access to HIPE data before the
cancer diagnosis. Furthermore under recording of comorbid disease in the HIPE data is a potential limitation and as
other measures such as functional status were not available
to us, it is probable we have under estimated the level of
comorbid disease in our patient sample. Notwithstanding,
we have shown short term survivors have more comorbid
disease than longer term survivors and the odds of early
mortality increases with increased comorbidity. Given this,
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earlier referral for palliative care assessment could not only
improve the patient experience at end of life but might also
yield economic benefits.
Stage

Our study also reports short term survivors were more
likely to have tumours which are less well characterised,
(i.e. not staged and histologically unspecified), than patients
who survive longer. Current national guidelines recommend patients with stage IV non-small-cell lung cancer
should be offered concurrent specialist palliative care and
standard oncological care at initial diagnosis [39] (see
recommendation 2.8.1.1 page 109). It further recommends
all patients with advanced stage lung cancer should have
their palliative care needs assessed. Using the stage IV
criteria as an indicator for palliative care just over 50% of
the short-term survivors from our study would be identified
and this highlights the need for additional prognostic
indicators for early assessment.
Place of death

Our rate of death in acute hospitals of 49% for lung cancer
decedents is higher than that reported by Bekelman et al.
for lung cancer decedents aged 65 years or older in acute
hospitals in England (42.6%), Germany (45%), The
Netherlands (29.5%), Norway (46.5%) and the United
States (20.2)% and lower than Canada (54.1%) [8]. The
higher percentage of hospital deaths in our study is
partially due to the high rates in the short term survivors,
but also the Bekelman study was restricted to deaths for 1
year (2010) while our study had a broader time frame of 8
years and included all lung cancer patients. Moves to
reduce deaths in acute hospitals adopted in the United
States and the Netherlands (as described by Bekelman et
al.) have been effective however without reporting place of
death by survival time, it is unclear whether they benefit
short term survivors.
In an economic evaluation of specialist palliative care
services in three parts of Ireland which have heterogeneous
structures and resources for these services, Brick et al.
found that an area with well-developed specialist palliative
care services and, where its role is understood, is likely to
have more referrals and that these will in general be earlier
[40]. O’Leary et al., in a study of one specialist palliative
care service in Ireland over a 6-month period found late
referral to palliative care was associated with receiving specialist palliative care in one care setting only but receiving
care across multiple settings supported people to stay at
home for longer [41].
Death within 30 days of diagnosis means there is little
time to determine and put appropriate care plans in
place and death in hospital for these patients might be
entirely appropriate. In this context triggers for early
assessment of palliative care for newly diagnosed lung
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cancer patients are very important so that the best care
can be provided as soon as possible whether in hospital,
in the community or at home.
Strengths and limitations

A strength of our study is the use of high quality population
based cancer registry data which has been verified and
augmented by linkage to hospital episode data to death and
certificate data. Linked datasets provide novel opportunities
for research at the population level, however there are
limitations to their use. For data confidentiality reasons, we
cannot access hospital episode data for patients before a
cancer diagnosis, so cannot examine health care utilisation
leading to diagnosis. This information would facilitate a
more accurate profile of the short term survivors in particular; multiple morbidities, especially in elderly patients,
might explain short survival and/or post-mortem diagnoses
of lung cancer. In this study 10% of lung cancer cases
recorded by NCRI had no corresponding HIPE record.
Failure to find a match can occur for several reasons
including: typographical errors in fields used for matching,
missing data on either system or no mention of cancer on
the HIPE record, in which case the record would not be
made available to NCRI. A cross reference of HIPE data
with death certificate data indicate 5% of patients with
place of death recorded as hospital do not have a HIPE
record and we estimated 3% of these died in private hospitals who do not provide HIPE data.

Conclusion
A major focus of end-of-life care research has been to
identify cohorts of patients who may be near end of life
and would benefit from palliative care [42, 43].
We have shown a high proportion of lung cancer patients
who die within 30 days of diagnosis are older, have comorbid disease and are admitted through the emergency
department. These characteristics, available at diagnosis,
may be useful prognostic factors to guide decisions on early
assessment for palliative care for lung cancer patients.
Further research is needed on the palliative care needs
of elderly patients admitted through the emergency
department with suspected lung cancer.
Patients who die shortly after diagnosis are more likely
to die in hospital so reporting place of death by survival
time may be useful to evaluate interventions to reduce
deaths in acute hospitals. It would also highlight sub groups
of patients who might benefit from early assessment for
and referral to palliative care.
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